AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A compound of general formula (1):



(1)

in which:

X represents a carbon atom linked to a hydrogen atom (CH) and Y represents a nitrogen atom, or

X represents a nitrogen atom and Y represents a carbon atom linked to a hydrogen atom (CH);

A represents a methyl (CH_3), fluoromethyl (CH_2F), cyano (C≡N), hydroxyl (OH) or methoxy (OCH_3) radical or a chlorine or fluorine atom;

B represents a chlorine atom or a fluorine atom;

D represents a hydrogen atom, a chlorine atom, a fluorine atom, a cyano group (C≡N) or a trifluoromethyl group (CF_3);

E represents a hydrogen, fluorine or chlorine atom;

the addition salts thereof ~~and optionally the hydrates of the addition salts~~ with pharmaceutically acceptable mineral acids or organic acids, and also the tautomeric forms thereof.

2. (Original) The compound of general formula (1) as claimed in claim 1, in which:

B and E each represent a fluorine atom, and

D represents a chlorine atom.

3. (Currently amended) The derivative as claimed in claim 1, characterized in that it is chosen from the group consisting of:

(3-chloro-4-fluorophenyl)(4-fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)amino]methyl}piperidin-1-yl)-methanone;

(3,4-dichlorophenyl)(4-fluoro-4-{[(5-methylpyrimidin-2-ylmethyl)amino]methyl}piperidin-1-yl)methanone;

(3-chloro-4-fluorophenyl)(4-fluoro-4-{[(6-methyl-pyridazin-3-ylmethyl)amino]methyl}piperidin-1-yl)-methanone;

(3,4-dichlorophenyl)(4-fluoro-4-{[(6-methylpyridazin-3-ylmethyl)amino]methyl}piperidin-1-yl)methanone;

the addition salts thereof ~~and optionally the hydrates of the addition salts~~ with pharmaceutically acceptable mineral acids or organic acids, and also the tautomeric forms thereof.

4. (Cancelled)

5. (Currently amended) A pharmaceutical composition, characterized in that it contains as active ingredient at least one compound as claimed in any one of claims 1 to 3, or 12-14, combined with an inert pharmaceutical support or pharmaceutically acceptable vehicle.

6-8. (Cancelled)

9. (Currently amended) A method for the treatment of depression comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1 to 3, or 12-14.

10. (Currently amended) A method for the treatment of pain comprising administering to a patient in need thereof an effective amount of a compound according to any one of claims 1 to 3, or 12-14.

11. (Cancelled)

12. (New) The compound of general formula (1) as claimed in claim 2, in which A represents a methyl radical.

13. (New) The compound of general formula (1) as claimed in claim 2, in which X represents a nitrogen atom.

14. (New) The derivative as claimed in claim 1, characterized in that it is (3-chloro-4-fluorophenyl)-(4-fluoro-4{[(5-methylpyrimidin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl)-methanone, the addition salts thereof with pharmaceutically acceptable mineral acids or organic acids, and also the tautomeric forms thereof.

15. (New) The method of claim 9 or claim 10, wherein the compound is administered by oral, nasal, sublingual, rectal, or parenteral administration.

16. (New) The method of claim 15, wherein the administration is oral.

17. (New) The method of claim 15, wherein the administration is parenteral.